Article Text

PDF
FRI0319 Drug Retention Rates of Biologic Monotherapies for Patients with Rheumatoid Arthritis in Daily Clinical Practice; Using Multicenter Registry in Japan
  1. H. Matsubara1,
  2. T. Kojima2,
  3. N. Ishiguro2
  4. on behalf of TBC Study Group
  1. 1Department of Orthopedic Surgery, Handa Municipal Hospital, Handa
  2. 2Department of Orthopedic Surgery, Nagoya University Graduate Scool of Medicine, Nagoya, Japan

Abstract

Background In general, drug retention rate reflects the effectiveness and tolerability of the drug. In Japan, seven biological agents have been approved for the treatment of rheumatoid arthritis (RA). There is few data comparing the retention rates between biological monotherapies for RA patients in daily clinical practice.

Objectives The purpose of this study is to compare the drug retention rates of three biological monotherapies with different target molecules, etanercept (ETN), tocilizumab (TCZ), abatacept (ABT).

Methods We collected the data from the patients who started monotherapies with ETN, TCZ, ABT as first-biologics since 2008 and registered in the multicenter, large cohort of RA patients (Tsurumai Biologics Communication Registry; TBCR). We surveyed the following information: demographic data, disease activity (DAS28-CRP) at the baseline of each biological treatment. Drug retention rates were calculated by the Kaplan-Meier analysis and compared using the log-rank test among groups. We investigated drug retention rates for discontinuation due to insufficient effectiveness (IE) and adverse events (AE). To compare risks of drug discontinuation due to IE and AE for patients treated with these biological agents, the Cox proportional hazard model was applied.

Results We analyzed 279 patients of 2072 patients registered in TBCR until March 2011 (141 patients in the ETN group, 63 patients in the TCZ group, 75 patients in the ABT group). The mean follow up time was 25.7 months. Table shows baseline characteristics of the groups (Table). The patients in the ABT group were older compared with other groups. Cumulative incidence rate for discontinuation due to insufficient effectiveness was significantly lower in the TCZ group (p=0.019, Fig.1A). Cumulative incidence rate for discontinuation due to adverse events was significantly lower in the ABT group (p=0.007, Fig.1B). Compared with TCZ group, the use of ABT was significantly associated with a lower risk of discontinuation due to AE (HR 0.081; 95% CI 0.009 to 0.737).

Conclusions We demonstrated that TCZ monotherapy had a lower discontinuation rate due to IE and that ABT monotherapy had a lower discontinuation rate due to AE.

Disclosure of Interest H. Matsubara: None declared, T. Kojima Speakers bureau: abbvie Japan, Chugai Pharmaceutical, Daiichi Sankyo Pharmaceutical, Eisai, Mitsubishi Tanabe Pharma, Pfizer Japan, Takeda Pharmaceutical, N. Ishiguro Speakers bureau: abbvie Japan, Chugai Pharmaceutical, Daiichi Sankyo Pharmaceutical, Eisai, Mitsubishi Tanabe Pharma, Pfizer Japan, Takeda Pharmaceutical

DOI 10.1136/annrheumdis-2014-eular.5755

Statistics from Altmetric.com

Request permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.